20 / 36
Crizotinib
(N=151)
Alectinib
(N=152)
Patients with events, n (%)
92 (61)
63 (41)
Median PFS, months
(95%
CI)
10.4 (11.1)
(7.7–14.6)
25.7 (NR)
(19.9–NR)
HR
(95% CI)
P-value (log-rank test)
0.50 ( 0.47 )
(0.36–0.70)
P<0.0001
0
20
40
60
100
1
3
6
9
12
15
18
21
24
27
30
80
Progression-free Survival (%)
Day
128
92
74
57
46
33
12
4
132
112
108
95
83
69
35
15
Alectinib
Crizotinib
151
152
2
Crizotinib
Alectinib
No. at Risk
Months
10.4 months (Profile 1014 10.9 m)
NR
S. Peters N Engl J Med 2017
ALEX
PFS (IRC) Alectinib vs Crizotinib